Should rheumatologists prescribe statins?

Joint Bone Spine

Volumn 77, Issue 2, 2010, Pages 93-95

  Soubrier, Martin ^a   Bruckert, Éric ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cardiovascular; HDL cholesterol; LDL cholesterol; Rheumatoid arthritis; Risk factors

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; MEDICAL SPECIALIST; PRESCRIPTION; RHEUMATOID ARTHRITIS;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHYSICIAN'S PRACTICE PATTERNS; RHEUMATIC DISEASES; RISK FACTORS;

EID: 77949567100     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.01.003     Document Type: Editorial

References (22)

1. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
2. Avina-Zubieta J.A., Choi H.K., Sadatsafavi M., et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59 (2008) 1690-1697
3. Soubrier M., Mathieu S., and Dubost J.J. Atheroma and systemic lupus erythematosus. Joint Bone Spine 74 (2007) 566-570
4. Hak A.E., Karlson E.W., Feskanich D., et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the Nurses' Health Study. Arthritis Rheum 61 (2009) 1396-1402
5. Gordon D.J., and Rifkind B.M. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med 321 (1989) 1311-1316
6. Davidson M.H., and Toth P.P. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol 100 11 A (2007) n32-40
7. Hahn B.H., Grossman J., Ansell B.J., et al. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 10 (2008) 213
8. Choy E., and Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68 (2009) 460-469
9. Popa C., van Tits L.J., Barrera P., et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 68 (2009) 868-872
10. McKenney J.M. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol 96 4A (2005) 60E-66E
11. Agence française de sécurité sanitaire des produits de santé. Prise en charge thérapeutique du patient dyslipidémique. 2005.
12. ANAES. Méthodes d'évaluation du risque cardiovasculaire global. 2004.
13. Soubrier M., Zerkak D., and Dougados M. Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem. J Rheumatol 33 (2006) 1766-1769
14. Wajed J., Ahmad Y., Durrington P.N., et al. Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. Rheumatology 43 (2004) 7-12 [Oxford]
15. Ansell B.J. Targeting the anti-inflammatory effects of high-density lipoprotein. Am J Cardiol 100 11 A (2007) n3-n9
16. Charles-Schoeman C., Khanna D., Furst D.E., et al. Effects of high-dose atorvastatin on anti-inflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 34 (2007) 1459-1464
17. Paraskevas K.I. Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 27 (2008) 281-287
18. McCarey D., McInnes I., Madhok R., et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 363 (2004) 2015-2021
19. van Denderen J.C., Peters M.J., van Halm V.P., et al. Statin therapy might be beneficial for patients with ankylosing spondylitis. Ann Rheum Dis 65 (2006) 695-696
20. Ridker P.M., and Solomon D.H. Should patients with rheumatoid arthritis receive statin therapy?. Arthritis Rheum 60 (2009) 1205-1209
21. Bruckert E., Hayem G., Dejager S., et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther 19 (2005) 403-414
22. Franc S., Dejager S., Bruckert E., et al. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 17 (2003) 459-465